Prions are self-propagating protein conformers that cause a variety of neurodegenerative disorders in humans and animals. Mouse models have played key roles in deciphering the biology of prions and in assessing candidate therapeutics. The development of transgenic mice that form prions spontaneously in the brain has advanced our understanding of sporadic and genetic prion diseases. Furthermore, the realization that many proteins can become prions has necessitated the development of mouse models for assessing the potential transmissibility of common neurodegenerative diseases. As the universe of prion diseases continues to expand, mouse models will remain crucial for interrogating these devastating illnesses.
Prion diseases are invariably fatal neurodegenerative disorders that include Creutzfeldt-Jakob disease (CJD) 2 in humans, scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cattle, and chronic wasting disease (CWD) in deer, elk, and moose. These diseases, sometimes referred to as the transmissible spongiform encephalopathies, are the only class of disease that can manifest in three distinct ways: sporadically, genetically, or by means of an infectious route. Prions, the causative agents in these diseases, are composed exclusively of a host-encoded protein, the prion protein (PrP). During prion disease, the cellular isoform of PrP (PrP C ) undergoes a profound conformational rearrangement into a misfolded isoform termed PrP Sc that is aggregation-prone and infectious (1, 2) . PrP Sc is self-propagating; binding of PrP Sc to PrP C leads to the conformational conversion of PrP C into an additional copy of PrP Sc . Not all PrP Sc molecules are the same; distinct strains of prions with differing biochemical, neuropathological, and transmission properties are believed to result from conformational differences in PrP Sc (3, 4) . The most common biochem-ical method for differentiating PrP C from PrP Sc is based on the observation that PrP Sc is partially resistant to protease digestion (5) . Whereas PrP C is completely degraded by proteases such as proteinase K (PK), digestion of PrP Sc with PK results in a truncated PK-resistant PrP fragment sometimes referred to as or PrP res .
PrP C is a neuronal glycoprotein that is anchored to the cellular membrane by a glycosylphosphatidylinositol (GPI) anchor. The structure of PrP C consists of two domains: an ␣-helical C-terminal domain and a flexibly disordered N-terminal domain (6) . The function of PrP C remains largely enigmatic because knock-out mice in which the PrP gene has been ablated do not exhibit overt phenotypic deficits, with the possible exception of a late onset peripheral myopathy (7, 8) . However, PrP knock-out mice are completely resistant to prion disease (9) , demonstrating that PrP is essential for prion replication and propagation.
Characteristics of Prion Disease in Mice
The two most commonly used laboratory animals for studying experimental prion disease are hamsters and mice. Although disease incubation periods in hamsters can be shorter (10) , mice are generally preferred due to ease of maintenance and the existence of tools for manipulating the mouse genome. The mouse models available for studying PrP prion diseases are arguably far superior to those available for any other human neurodegenerative illness. In fact, it is somewhat inappropriate to refer to these as "models" of prion disease because prion-challenged mice actually develop bona fide prion disease and recapitulate all of the neuropathological and biochemical hallmarks of the human and animal diseases. In contrast, mouse models of Alzheimer disease (AD) are non-ideal because they typically develop senile plaques and cognitive deficits, but not the neurofibrillary tangles and associated neuron loss seen in AD patients (11) . Similarly, mouse models of Parkinson disease (PD) develop a neurodegenerative disease, but the brains of spontaneously sick mice do not contain the Lewy bodies that are found in the brains of patients with PD (12) .
The most frequently used paradigm for studying prion disease in mice takes advantage of the infectious nature of prions. A typical prion bioassay involves the intracerebral inoculation of wild-type (WT) mice with a sample containing mouse-passaged prions (13) . Following a 4 -5-month incubation period, which is dependent on the prion strain used, inoculated mice begin to develop progressive clinical signs of neurological illness including ataxia (uncoordinated movement), tail rigidity, and kyphosis (hunched back) and will eventually succumb to prion disease. This assay is remarkably robust. If a high-titer prion sample is used, 100% of the inoculated mice will die of prion disease within a few weeks, or less, of each other. The brains of prion-infected mice recapitulate all of the neuropathological hallmarks of prion diseases in humans and animals including spongiform degeneration (vacuolation of the brain), deposition of misfolded PrP, and prominent astrocytic gliosis ( Fig. 1, left column) . Furthermore, PK-resistant PrP Sc , the bio-chemical signature of PrP prion disease, can readily be detected in brain homogenates prepared from clinically ill prion-inoculated mice. Although intracerebral inoculation is the most efficient method for transmitting prion disease to mice, peripheral routes of inoculation can also initiate prion disease, although the resultant incubation periods are usually longer.
A major advantage of the WT mouse prion bioassay is that it can be used to quantify levels of infectivity (i.e. prion titers) in biological samples. Two approaches are commonly used. The most accurate, but time-consuming, method is the end point titration bioassay. In this assay, groups of mice are inoculated with a series of 10-fold dilutions of the test sample, and the titer is measured by determining the dilution at which only 50% of the inoculated animals develop disease. A quicker, but less accurate, method is the incubation time bioassay, which takes advantage of the observation that for a given prion strain, incubation periods in prion-inoculated mice or hamsters are inversely related to the dose of prions inoculated (14) . Thus, prion titers can be estimated by comparing incubation periods with a calibration curve created using a sample of known titer.
Mouse Models for Studying Prion Diseases of Humans and Animals
Although the prion bioassay in WT mice described above is considered to be the "gold standard" for interrogating prion disease in mice, it suffers from some important drawbacks. First, the assay is time-consuming and expensive. Using transgenic (Tg) mice that overexpress mouse PrP in the brain greatly accelerates the disease process. In these mice, the incubation period for mouse-passaged scrapie strains such as RML is reduced to ϳ50 -60 days (15, 16) , allowing prion titers to be measured more rapidly (17) . A distinct approach to reducing the time needed to diagnose prion disease in mice without requiring PrP overexpression is bioluminescence imaging (BLI). Tg mice that express firefly luciferase under the control of the glial fibrillary acidic protein (GFAP) promoter exhibit an increase in brain BLI signal beginning at ϳ60 days after inoculation, less than half the time necessary for the appearance of clinical signs of disease (18) . This approach has the added benefit that the results obtained are quantitative and do not rely on the subjective assessment of neurological signs in mice. Using BLI in combination with Tg mice that overexpress PrP further reduces the time required to diagnose disease (19) .
A second, more important drawback is that the standard WT mouse bioassay is only suitable for studying mouse-passaged prion strains. Inoculation of WT mice, which express mouse PrP, with prion strains more relevant to humans, such as those causing CJD, which are composed of human PrP Sc , leads to inefficient disease transmission due to so-called species or transmission barrier effects (20 -22) . However, utilizing Tg mice that express a PrP gene matched to the prion strain under investigation can mitigate these effects. For example, Tg mice that express human PrP are susceptible to CJD prions (23, 24) , Tg mice that express sheep PrP are susceptible to scrapie prions (25) , and Tg mice that express bovine PrP are susceptible to BSE prions (26, 27) . A list of commonly used Tg lines to study various prion diseases is shown in Table 1 (see also Ref. 28) . For efficient disease transmission to occur in Tg mice, the endogenous mouse PrP gene needs to be removed, likely because it interferes with the conversion of heterologous PrP species, potentially by binding to an essential prion replication cofactor (24) . Although Tg mice expressing PrP genes from various species permit the analysis of a variety of prion strains within a reasonable timeframe, they are not without their issues. High levels of PrP overexpression in mice can cause late-onset spontaneous disease (29) , and the use of heterologous promoters to drive PrP expression may not accurately mimic the normal pattern of PrP expression in the brain (16) . An alternative approach is to use knock-in (or gene-targeted) mice in which the murine PrP gene is replaced with the PrP gene from a different species. This approach has the benefit that the heterologous PrP molecule is expressed at physiological levels and under the control of its native promoter. However, the incubation periods, especially for sporadic CJD prions, can be very long in these mice (30, 31) .
Despite robust overexpression of bovine or human PrP in the brains of Tg mice, the incubation periods for BSE and sporadic CJD prions in these respective mice are lengthy ( Table 1 ). For the MM1 subtype of sporadic CJD prions, expressing chimeric mouse/human PrP molecules in the brain has substantially decreased the incubation period (32, 33) . In Tg mice expressing a chimeric mouse/human PrP molecule with only six humanspecific residues, the incubation period for MM1 prions was ϳ80 days (33) , approximately half the amount of time it takes Tg mice expressing human PrP to develop disease. Unfortunately, the benefits of this chimera approach do not appear to apply to all CJD strains (34) .
Assessing Prion Disease Therapeutics Using Mouse Models
The robust Tg and WT mouse models available for prion disease have provided an excellent vehicle for testing the efficacy of candidate anti-prion compounds. Small molecules, such as compound B (cpd-B), Anle-138b, and the 2-aminothiazoles, were capable of significantly extending the disease incubation period in both Tg and WT mice following challenge with prions (19, (35) (36) (37) . However, an important observation that has emerged from these therapeutic studies is that the efficacy of anti-prion compounds is highly strain-specific. Compounds that were effective at extending the lives of Tg mice infected with mouse-passaged scrapie prions had no effect in Tg mice challenged with human CJD prions (37) . Thus, going forward, it will be imperative to perform therapeutic efficacy experiments in Tg mice expressing human PrP that have been inoculated with human prions to assess any potential translational utility.
Tg mice have also provided clues that decreasing levels of PrP C during prion disease may constitute an excellent therapeutic strategy. Prion inoculation of mice in which PrP production can be turned off using the Cre-lox system has revealed that prion disease-specific neuropathological and behavioral changes can be halted by reducing PrP C levels (38, 39) . Similar results have been obtained in Tg mice in which PrP C levels can be precisely controlled using doxycycline (40) . A distinct strategy is to target downstream pathways that are responsible for PrP Sc -mediated neurotoxicity. Indeed, targeting the unfolded protein response in Tg mice overexpressing mouse PrP has resulted in abrogation of PrP Sc -induced neuropathological changes (41) .
Spontaneous Generation of Infectious Prions in Mice
In humans, sporadic and genetic forms of prion disease account for ϳ99% of all cases. In these illnesses, prions form spontaneously in the brain in the absence of any exogenous source of PrP Sc . In genetic prion disease, mutations in the gene encoding PrP result in highly penetrant disease classified as CJD, Gerstmann-Sträussler-Scheinker (GSS) disease, or fatal familial insomnia (FFI), depending on the specific mutation. Results obtained from generating Tg mice expressing PrP molecules containing a mutation linked to genetic prion disease have been somewhat disappointing. Spontaneous neurological disease and prion disease-specific neuropathological changes have failed to manifest in many of these lines, despite the robust overexpression of mutant PrP (42) (43) (44) . In contrast, many other Tg lines do develop spontaneous neurologic dysfunction and exhibit some prion disease-specific neuropathology, although none of them exhibit the stereotypical PK-resistant PrP signature that is observed in patients with genetic CJD ( Table 2) . Until recently, transmission of disease from these spontaneously sick mice to Tg or WT mice expressing WT PrP (that do not themselves develop a spontaneous neurological illness) has proven challenging, calling into question whether true de novo prion formation occurs in the brains of these Tg mice.
The most extensively studied human mutation in Tg mice is P102L, which causes GSS. Tg mice overexpressing mouse PrP containing the corresponding mutation (P101L) develop a spontaneous neurodegenerative disease and exhibit deposition of misfolded PrP in their brains (42, 45, 46) . However, low copy number Tg mice that express physiological amounts of the mutant protein do not develop spontaneous disease (46), suggesting that overexpression is necessary for the disease to man- ifest within the normal lifespan of a mouse. Spontaneously ill mice with the P101L substitution do not exhibit any classical PK-resistant PrP in their brains, but do have some mildly PKresistant PrP that can be detected by performing the PK digestion reaction at cold temperatures (46, 47) . Disease can be transmitted from mice expressing high amounts of the mutant protein to mice expressing lower amounts of the protein, but only if the lower-expressing lines themselves develop late-onset spontaneous disease (42, 46, 48, 49) . This has led some investigators to characterize these results as disease acceleration as opposed to true disease transmission. Although Tg mice overexpressing human PrP containing the P102L mutation failed to develop disease (43) , Tg mice expressing cow PrP containing the corresponding mutation did (50) , suggesting that other residues in PrP are important for controlling the disease phenotype in mice.
Other mutations that have given rise to spontaneous neurodegeneration in Tg mice include A117V (51) and a nine-octapeptide repeat insertion in the N terminus of PrP (52), both of which cause GSS in humans, as well as D178N (53), which causes CJD when in cis to a valine residue at codon 129 in PrP. However, disease transmissibility has not been demonstrated for any of these lines. The E200K mutation, which is a common cause of genetic CJD in humans, causes spontaneous neurological illness in Tg mice when inserted into a chimeric mouse/ human PrP molecule (54), but not in mouse PrP (42) or human PrP (43) . Tg mice expressing a GPI-anchorless PrP mutant similar to those produced in certain types of GSS develop a spontaneous disease that is accompanied by large amounts of PrPcontaining amyloid plaques in the brain as well as a small PK-resistant PrP fragment that is reminiscent of those found in the brains of GSS patients (55) . This disease was readily transmissible to Tg mice expressing WT PrP, proving that anchorless prions were formed de novo in the brains of these spontaneously sick animals.
Because Tg mice expressing low levels of mutant PrP have generally failed to develop spontaneous disease, it was expected that knock-in mice in which endogenous WT mouse PrP is replaced with a mutant PrP molecule would behave similarly. Indeed, knock-in mice expressing the P101L mutation failed to develop any spontaneous illness (56) . In contrast, knock-in mice expressing the mouse equivalents of the D178N (which causes FFI in humans when expressed with methionine at codon 129) or E200K mutation both developed spontaneous disease (57, 58) . Although the clinical signs and neuropathological changes in these mice were subtle, the spontaneous diseases could be transmitted to knock-in mice expressing a similarly epitope-tagged, but otherwise WT, PrP molecule. Thus, although knock-in mice may not be particularly suitable as a medium for testing therapeutics due to the long disease incubation periods, they may be useful for understanding how prions form spontaneously in the absence of protein overexpression.
Recent studies have described the unexpected finding that infectious prions can also be generated spontaneously in the brains of Tg mice in the absence of any disease-associated mutations in PrP. In one study, Tg mice overexpressing a chimeric mouse/elk PrP molecule that contains a so-called "rigid TABLE 2 Transgenic and knock-in mouse models of genetic and sporadic prion disease loop" structure were found to develop spontaneous signs of neurological illness as well as prion disease-specific neuropathological changes (59) . This illness could be transmitted to Tg mice overexpressing mouse PrP and eventually led to the appearance of stereotypical PK-resistant PrP following multiple passages. A similar disease was observed in Tg mice expressing chimeric mouse/horse PrP, which also contains a rigid loop structure, although it is currently unknown whether this disease is transmissible (60) . The characterization of Tg mice expressing WT bank vole PrP provided another surprise. Unlike mice, bank voles are highly susceptible to a wide range of prion strains isolated from numerous species, including humans (61) (62) (63) . Tg mice expressing the Ile-109 polymorphic variant of bank vole PrP develop a spontaneous neurodegenerative disease that recapitulates all of the neuropathological hallmarks of prion disease (Fig. 1, right column) (64) . This disease was rapidly transmissible to Tg mice expressing bank vole PrP, with incubation periods as short as 35 days, and could also be transmitted to Tg mice overexpressing mouse PrP and to WT mice. Interestingly, despite the occurrence of rapid disease and profound prion-specific neuropathology, only mildly PK-resistant PrP was found in the brains of ill mice, suggesting that they may be useful for investigating hypothetical neurotoxic PrP entities such as "PrP L " (22) . Moreover, because these mice express a non-mutant PrP molecule, they may be suitable for probing the mechanisms that lead to spontaneous prion formation in sporadic CJD patients.
Mouse Models for Studying the Expanding Universe of Prion Diseases
There is an emerging consensus that other human neurodegenerative illnesses, including much more common diseases such as AD and PD, are caused by the formation and spread of self-propagating protein conformations (i.e. prions) in the brain (65, 66) . However, the prions in these diseases are not composed of misfolded PrP; instead, each disease is associated with a distinct aggregation-prone protein that becomes a prion. In PD and multiple system atrophy (MSA), prions are composed of ␣-synuclein protein, whereas in the tauopathies such as frontotemporal dementia and chronic traumatic encephalopathy, the prions are composed of Tau protein. Two distinct prions are associated with AD: self-propagating conformations of both amyloid ␤ peptide (A␤) and Tau protein are present.
Much of the evidence for the prion-like nature of A␤, ␣-synuclein, and Tau has come from experiments in which the intracerebral inoculation of susceptible Tg mice with protein aggregates induces or accelerates the deposition of misfolded protein in the brain. For the majority of cases, these experiments have required the use of Tg mice that overexpress either WT or mutant protein in the brain and which typically develop a late-onset spontaneous disease with concomitant protein aggregation and deposition (Table 3 ). It should be noted that although these inoculation paradigms have provided important insight into the biology of neurodegenerative diseases, they suffer from several limitations (67) .
The first non-PrP, neurodegenerative disease-associated protein shown to exhibit prion-like behavior was A␤. Intracerebral inoculation of the APP23 mouse model of AD, which expresses Swedish mutant human amyloid precursor protein (APP) and overproduces WT A␤, with AD or aged APP23 mouse brain homogenates induces or "seeds" the localized deposition of A␤ in the brain (68) . Although these transmissions are somewhat artificial in nature, several additional experiments in mice have bolstered the notion that A␤ aggregates are prions. First, induction of A␤ deposition can be achieved in Tg mice expressing WT human APP that do not develop a spontaneous amyloidosis (69); induction of A␤ deposition in non-Tg mice has not yet been demonstrated, although induced A␤ deposits have been observed in AD-inoculated marmosets following long incubation periods (70) . Second, cerebral A␤ deposition can be initiated by peripheral inoculation with A␤ aggregates (71) , mimicking the neuroinvasive properties of PrP Sc . Finally, A␤ amyloid fibrils purified from the brains of Tg mouse models of AD as well as aggregates composed exclusively of synthetic A␤ are sufficient to induce widespread deposition of A␤ in the brain (72) , proving that A␤ itself is the self-propagating agent. Unlike in PrP prion-infected mice, Tg mice with prominent cerebral A␤ deposition do not exhibit overt clinical signs of neurologic illness, hindering the monitoring of A␤ deposition in living animals. This obstacle has been overcome by performing BLI of A␤ plaque-associated astrocytic gliosis. Bigenic mice expressing both mutant human APP and a luciferase reporter driven by the Gfap promoter exhibit an age-dependent increase in the brain BLI signal, which can be accelerated by intracerebral inoculation with A␤ aggregatecontaining samples (72, 73) . Induction of Tau deposition by intracerebral injection of brain homogenate from either aged Tg mice expressing mutant human Tau or patients with various tauopathies has been observed in Tg mice expressing WT human Tau, which do not spontaneously develop Tau aggregates in their brains (74, 75) . Mild induction of Tau deposition was also obtained in non-Tg mice inoculated with human tauopathy brain material (75) . As with A␤, recombinant Tau fibrils are sufficient to accelerate Tau deposition in Tg mice expressing mutant Tau (76) . Arguably, the most convincing demonstration of the prion-like behavior of a non-PrP protein has been provided with ␣-synuclein. Although inoculation of Tg mice with A␤ or Tau aggregates leads to an induction of cerebral protein deposition, induction or acceleration of clinical signs of neurologic illness has not yet been shown in any transmission experiment. In contrast, inoculation of Tg mice expressing a mutant (A53T) human ␣-synuclein allele, which causes a genetic form of PD, with recombinant ␣-synuclein fibrils or brain homogenate from spontaneously ill A53T Tg mice induces ␣-synuclein aggregation and deposition in the brain, accelerates the appearance of clinical signs of disease, and results in death (77, 78) . Although these initial transmission experiments utilized Tg mice that ultimately developed spontaneous disease, identical results have been achieved in Tg mice expressing lower amounts of the mutant protein that do not spontaneously develop a neurological illness (79) . Furthermore, robust ␣-synuclein deposition can be induced in non-Tg mice using synthetic ␣-synuclein fibrils (80, 81) . Most impressively, brain homogenates from MSA patients transmit disease rapidly to Tg mice expressing low levels of mutant ␣-synuclein (79), arguing persuasively that ␣-synuclein prions cause MSA. The unquestionable similarities between the transmission of MSA prions to Tg mice expressing human ␣-synuclein and the transmission of CJD prions to Tg mice expressing human PrP make it hard to dismiss the notion that ␣-synuclein can become a prion.
Conclusions and the Next Generation of Animal Models
Although prion-infected cell culture systems and in vitro protein misfolding assays have undoubtedly contributed to our knowledge of prion diseases and other neurodegenerative disorders, many aspects of these diseases, including the prion-like spread of protein aggregation throughout the brain, can only be accurately studied in an animal. As further emphasis is placed on translational research, particularly in the area of drug development, mouse models will continue to serve as the system of choice for assessing biological problems in vivo. Although the currently available mouse models for prion disease are adequate in many respects, there is certainly room for improvement. First, it has been puzzling why the brains of Tg mice expressing a genetic prion disease-causing mutation have failed to exhibit stereotypical PK-resistant PrP Sc (i.e. PrP 27-30), despite the presence of prion disease-specific neuropathology. Perhaps human brain-specific factors or prolonged incubation periods (that are impossible to achieve within the normal lifes-pan of a mouse) are required for this conformation of PrP Sc to arise spontaneously. Second, it would be of great benefit to discover methods for accelerating disease incubation periods in Tg mice, particularly for CJD prion strains, to increase research throughput and decrease the costs associated with lengthy bioassays.
Although Tg mice have been the paradigm for disease modeling over the last few decades, the next generation of animal models for prion diseases may rely more heavily on the use of Tg rat models of disease. Recent advances in molecular biology have greatly facilitated the manipulation of the rat genome and thus the generation of knock-out, knock-in, and Tg rats (82, 83) . Rats are generally considered to be better suited as models for human neurological diseases than mice because of their abilities to exhibit more complex behaviors and their larger brain sizes (84) . Indeed, the recently described TgF344-AD rat model may constitute the most accurate animal model of AD to date (85) . Moving forward, rat models of prion and related diseases will likely be critical tools for studying the formation and spread of prions in the brain.
